Buerger’s Disease – Comprehensive Medical Guide

Overview

Buerger’s disease, also called thromboangiitis obliterans (TAO), is a rare, non‑atherosclerotic inflammatory disease that affects small‑ and medium‑sized arteries and veins, most often in the arms and legs. The inflammation causes clot formation (thrombus) that can block blood flow, leading to tissue ischemia and, in severe cases, gangrene.

Although the exact cause is unknown, the disease is strongly linked to tobacco use. It typically presents in young adult males who smoke, but women who use tobacco can be affected as well.

Key statistics

• Global prevalence: estimated 0.5–1.5 cases per 100,000 people.¹
• In the United States, ≈ 5–10 % of all peripheral arterial disease (PAD) patients have Buerger’s disease.²
• Mean age at diagnosis: 35–45 years.³
• Male‑to‑female ratio historically 9:1, but recent data from Asian cohorts show a narrowing gap (≈ 4:1).⁴

Symptoms

Symptoms result from reduced blood flow and can vary depending on which limb(s) are involved.

Upper Extremities

• Pain or cramping in the fingers or hands, especially during use (claudication).
• Coldness and numbness when exposed to low temperatures.
• Raynaud‑like phenomenon – color changes (white → blue → red) in the fingertips.
• Ulcers or gangrene on the fingertips or tips of the nose.

Lower Extremities

• Leg or foot pain on walking a short distance (often < 100 m).
• Rest pain that worsens at night and may awaken the patient.
• Cold, pale, or bluish toes that do not improve with warming.
• Superficial ulcers on the toes, heels, or the dorsal foot.
• Dry gangrene (blackened, painless tissue) in advanced disease.

Systemic/General Symptoms

• Fever and malaise during active inflammation (rare).
• Weight loss if ulcers become infected.

Causes and Risk Factors

While the precise trigger remains unknown, research points to an immune‑mediated reaction to components of tobacco smoke.

Primary Cause

• Tobacco exposure – both smoking and chewing tobacco are the strongest risk factor. 100 % of patients in most series have a history of tobacco use.⁵

Additional Risk Factors

• Age: Most cases are diagnosed before age 50.
• Gender: Historically male, but rising incidence in women in regions with high smoking rates.
• Geography/ethnicity: Higher prevalence in East Asian, Middle Eastern, and South Asian populations.
• Genetic susceptibility: Certain HLA‑A9 and HLA‑B5 alleles have been associated with increased risk.
• Other tobacco‑related conditions: Co‑existing Raynaud’s phenomenon, peripheral neuropathy, or other vasculitides can increase suspicion.

Diagnosis

Diagnosing Buerger’s disease is primarily one of exclusion—ruling out atherosclerosis, diabetes, and other vasculitides.

Clinical Criteria (Shionoya Criteria)

1. History of tobacco use.
2. Onset before age 45.
3. Presence of distal extremity ischemia (pain, ulcers, gangrene).
4. Absence of atherosclerotic risk factors such as diabetes, hyperlipidemia, or hypertension.
5. Arteriographic evidence of segmental occlusion with collateral vessels.

Diagnostic Tests

• Ankle‑Brachial Index (ABI): Values < 0.90 suggest peripheral arterial disease; markedly low values (< 0.4) are common in Buerger’s.
• Doppler Ultrasound: Shows occlusion of tibial and radial arteries with preserved proximal flow.
• Angiography (CT or MR): Reveals “corkscrew” collaterals and multifocal segmental narrowing.
• Laboratory work‑up: CBC, ESR/CRP (often normal or mildly elevated), fasting glucose, lipid panel—to exclude other causes.
• Skin/arterial biopsy (rarely needed): Shows acute and chronic inflammatory infiltrates with occluding thrombus.

Treatment Options

Because the disease is strongly linked to tobacco, cessation is the cornerstone of therapy.

1. Lifestyle Modification

• Complete tobacco abstinence (no cigarettes, cigars, e‑cigarettes, or smokeless tobacco). Relapse rates exceed 50 % without structured support.
• Smoking‑cessation programs: Behavioral counseling, nicotine‑replacement therapy (NRT), bupropion, or varenicline. Choice should be individualized.
• Exercise therapy: Supervised walking program 3‑5 times per week improves collateral circulation.
• Cold avoidance: Keep extremities warm; wear insulated gloves and socks.

2. Pharmacologic Therapy

• Antiplatelet agents – aspirin 81–325 mg daily (or clopidogrel 75 mg) reduce thrombus formation.⁶
• Vasodilators – calcium channel blockers (e.g., nifedipine) can improve Raynaud‑type symptoms.
• Prostaglandin analogs – intravenous iloprost or oral pentoxifylline may relieve rest pain and promote ulcer healing, though evidence is moderate.
• Analgesics – acetaminophen or low‑dose opioids for severe rest pain, used sparingly.

3. Interventional Procedures

• Sympathectomy (surgical or chemical): Interrupts sympathetic nerves to improve blood flow; benefits are often temporary and reserved for refractory cases.
• Endovascular therapy: Balloon angioplasty or stenting is less effective because lesions are often distal and fibrotic.
• Bypass surgery: Autologous vein grafts can salvage a limb when disease is limited to a short segment and the patient remains tobacco‑free for at least 6 months.
• Spiral vein grafts or arterial reconstruction – experimental, performed in select centers.

4. Wound Care & Infection Management

• Regular debridement, moist dressings, and off‑loading of pressure points.
• Systemic antibiotics for cellulitis or osteomyelitis, guided by cultures.
• Hyperbaric oxygen therapy may accelerate healing of chronic ulcers.

Living with Buerger’s Disease

Effective self‑management revolves around protecting the extremities and maintaining tobacco abstinence.

Daily Tips

• Temperature control: Avoid rapid temperature changes; use heat packs (not hot water) for painful cold toes.
• Foot care: Inspect feet daily for cracks, blisters, or discoloration; file calluses gently; keep nails trimmed.
• Appropriate footwear: Soft, well‑fitted shoes with a wide toe box; consider custom orthotics to off‑load pressure points.
• Hydration & nutrition: Adequate protein intake (1.0–1.2 g/kg) supports wound healing; a diet rich in omega‑3 fatty acids may modestly reduce inflammation.
• Regular follow‑up: At least every 3–6 months with a vascular specialist, even if asymptomatic.

Psychosocial Support

• Joining a support group for tobacco cessation or chronic limb‑ischaemia can alleviate anxiety and improve adherence.
• Consider counseling or cognitive‑behavioral therapy if quitting tobacco is particularly challenging.

Prevention

Because tobacco exposure is the single most modifiable factor, primary prevention focuses on eliminating tobacco use.

• Start anti‑smoking education in schools, especially in high‑prevalence regions.
• Implement workplace smoking bans and increase taxes on tobacco products.
• Screen high‑risk individuals (young smokers with limb pain) early with ABI testing.
• Encourage regular physical activity to improve peripheral circulation.

Complications

If untreated or if tobacco use continues, Buerger’s disease can progress to serious outcomes:

• Critical limb ischemia – persistent rest pain, non‑healing ulcers, or gangrene.
• Amputation – required in 20‑30 % of patients within 10 years of diagnosis when cessation fails.⁷
• Infection – cellulitis, osteomyelitis, and sepsis from ulcer colonization.
• Painful neuropathy due to chronic ischemia.
• Psychological impact – depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

---

Sources:

1. Khan, M. et al. “Epidemiology of Thromboangiitis Obliterans: A Systematic Review.” International Journal of Vascular Medicine, 2020.
2. Mayo Clinic. “Buerger Disease.” Retrieved 2024.
3. Centers for Disease Control and Prevention. “Buerger Disease Facts.” 2023.
4. Zhang, Y. et al. “Gender Differences in Buerger’s Disease in China.” Vascular Medicine, 2022.
5. Olin, J. “Smoking and Buerger’s Disease Pathogenesis.” Circulation Research, 2021.
6. Cleveland Clinic. “Buerger Disease Treatment Options.” 2023.
7. Ghosh, S. et al. “Long‑Term Outcomes After Buerger’s Disease Diagnosis.” Journal of Vascular Surgery, 2022.